Enhancing efficiency and safety in upstream biomanufacturing

The use of animal-free reagents in the upstream manufacturing of biologic drugs is a common standard in biomanufacturing, essential for enhancing consistency and safety. Insulin has emerged as a key component in cell culture for biomanufacturing, improving a wide array of processes such as monoclonal antibody (mAb) production in CHO cells, virus production in cells, stem cell culture performance, and production of viral vectors for gene therapy.

Another crucial element in cell-based vaccine production is Trypsin, which is essential for virus expansion and activation of specific virus particles, notably in the case of influenza. However, the use of animal-derived trypsin carries the inherent risk of introducing adventitious contaminants, potentially leading to cell culture infection with serious consequences for both patients and production continuity. The introduction of the new enzyme TrypsiNNex^® effectively addresses these safety and consistency concerns. As a high-purity, recombinantly produced, animal-free trypsin, TrypsiNNex^® ensures a more robust production process, effectively reducing the risk of contamination.

In this presentation, we will illustrate how both Insulin and TrypsiNNex^® significantly enhance the safety and efficiency of upstream biomanufacturing processes, thereby enhancing the overall efficiency of therapeutic biologics production. Furthermore, we will delve into how the implementation of reagents such as insulin plays a significant role in reducing overall upstream costs by increasing process efficiency.